Townsquare Capital LLC Purchases 2,808 Shares of Sanofi (NASDAQ:SNY)

Townsquare Capital LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 11.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,248 shares of the company’s stock after acquiring an additional 2,808 shares during the quarter. Townsquare Capital LLC’s holdings in Sanofi were worth $1,628,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in SNY. Bank of New York Mellon Corp increased its holdings in shares of Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC grew its holdings in Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the period. Federated Hermes Inc. raised its position in shares of Sanofi by 26.5% in the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after purchasing an additional 673,172 shares during the period. Finally, Natixis Advisors LLC lifted its stake in shares of Sanofi by 4.1% in the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after buying an additional 114,133 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on SNY shares. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $48.49 on Monday. The firm’s 50-day moving average is $52.80 and its 200-day moving average is $52.15. The company has a market cap of $123.06 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the company earned $2.55 EPS. Equities research analysts anticipate that Sanofi will post 4.28 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.